We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Postmarketing Draft Guidance Needs Details, Industry Says
Postmarketing Draft Guidance Needs Details, Industry Says
November 24, 2009
Stakeholders are telling the FDA that a July draft guidance on postmarketing studies should have described the safety signals the agency uses to determine
that a postmarket clinical trial or study will be required.